Endometriosis (EMS) is a common chronic gynecological disorder affecting 5%-10% of reproductive-age women, often causing infertility, dyspareunia, pain, and limitations in physical and sexual activities. This condition is defined by …
Human endometrium is the major target tissue for sex steroid hormones. The circulating steroid hormones in normal ovulatory cycles accurately control the proliferation and differentiation of the endometrial cells. Androgens, …
Endometriosis affects 10-15% of people assigned female at birth and can cause chronic pelvic pain and impair many domains of quality of life, such as fertility, mood and bladder, bowel …
Across studies, the percentage of individuals reporting regularly engaging in menstrual coitus ranges between 4% and 43%. Although no clinical guideline recommends avoiding sexual activity during menstruation, according to some …
Patients with pelvic floor disorders may experience a wide range of symptoms affecting one or more compartments of the pelvic floor (anterior/urinary, apical/reproductive, and posterior/gastrointestinal). Disorders affecting the pelvic organs …
Although the exact pathogenesis of central serous chorioretinopathy (CSC) remains unclear, some factors are known to be sex-specific. We aimed to investigate the incidence and systemic associations for CSC in …
We recognized a paucity of accessible, evidence-based, empowering patient-centred resources for those with endometriosis-associated dyspareunia. Affecting more than 50% of people with endometriosis, dyspareunia can significantly impact relationships, chronic pain …
Persistent pelvic pain is a prevalent condition that negatively impacts one's physical, psychological, social, and sexual wellbeing. Pain science education (PSE) involves learning about the biology of pain and is …
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …